Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clofarabine, Gemcitabine, and Busulfan Followed by Allogeneic Stem Cell Transplantation for Chronic Lymphocytic Leukemia (CLL)

NCT01629511 is registered in ClinicalTrials.gov with M.D. Anderson Cancer Center as lead sponsor.

NCT NCT01629511
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01629511 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clofarabine, Gemcitabine, and Busulfan Followed by Allogeneic Stem Cell Transplantation for Chronic Lymphocytic Leukemia (CLL)
Lead sponsor
M.D. Anderson Cancer Center
Phase
Phase 1/2
Overall status
Terminated
Start date
November 21, 2012
Completion date
April 25, 2018
Enrollment
15 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

allogeneic hematopoietic stem cell transplantation recipient, chronic lymphocytic leukemia, prolymphocytic leukemia, richter syndrome